Author： Burke J.F. Thomas S.
Publisher： Informa Healthcare
ISSN： 1354-3776
Source： Expert Opinion on Therapeutic Patents, Vol.9, Iss.2, 1999-02, pp. : 119-127
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
An overview of CNS drug discovery at Eli Lilly and Company
By Paul S.M.
European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. :
Access to resources
Recommend
Olanzapine document leak rocks the boat for Eli Lilly
Inpharma, Vol. 1, Iss. 1572, 2007-01 ,pp. :
Atomoxetine [Strattera; Eli Lilly] has been launched in the UK
Inpharma, Vol. 1, Iss. 1447, 2004-01 ,pp. :
Patent co-citation analysis of Eli Lilly & Co. patents
Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 3, 1999-03 ,pp. :
The thiazolidinedione pioglitazone [`Actos'; Eli Lilly Canada] has been approved by Health Canada
Inpharma, Vol. 1, Iss. 1257, 2000-01 ,pp. :